A Randomized, Double-Blind, Risperidone-Reference, Parallel-Group, Safety, and Tolerability Study of Vabicaserin (SCA-136) in Japanese Subjects With Acute Exacerbation of Schizophrenia.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2013
At a glance
- Drugs Vabicaserin (Primary) ; Risperidone
- Indications Schizophrenia
- Focus Therapeutic Use
- 19 Aug 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 22 Oct 2008 New trial record.